{"id":97464,"date":"2026-04-21T12:39:16","date_gmt":"2026-04-21T12:39:16","guid":{"rendered":"https:\/\/mybusinessfuture.com\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/"},"modified":"2026-06-10T14:01:35","modified_gmt":"2026-06-10T14:01:35","slug":"pharma-serialization-2-0-what-the-eu-fmd-revision-means-for","status":"publish","type":"post","link":"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/","title":{"rendered":"EU-FMD Revision: IT &amp; Supply Chain Impact"},"content":{"rendered":"<p style=\"display:inline-block;background:#c0392b;color:#fff;padding:4px 14px;border-radius:20px;font-size:0.85em;margin-bottom:18px;\">5 Min. Reading Time<\/p>\n<p style=\"line-height:1.8;margin-bottom:20px;\"><strong>Since February 9, 2019, pharmaceutical serialization has been mandatory in the EU. Every pack of prescription drugs carries a 2D data matrix code and a tamper-evident seal, with the data being fed into the European Medicines Verification System (EMVS). Six years later, the EU Commission is working on a revision of the Falsified Medicines Directive. What&#8217;s emerging is less of a break than a consolidation \u2013 with noticeable consequences for manufacturers&#8217; IT and supply chain architecture.<\/strong><\/p>\n<div style=\"background:#202528;color:#fff;padding:32px 36px;margin:32px 0;border-radius:8px;\">\n<p style=\"margin:0 0 18px 0;font-size:0.95em;font-weight:800;text-transform:uppercase;letter-spacing:0.2em;color:#c0392b;border-bottom:2px solid rgba(192,57,43,0.25);padding-bottom:12px;\">The Essentials at a Glance<\/p>\n<ul style=\"margin:0;padding-left:22px;color:rgba(255,255,255,0.92);line-height:1.6;\">\n<li style=\"margin-bottom:12px;\"><strong style=\"color:#c0392b;\">Compliance becomes architecture.<\/strong> The FMD revision elevates serialization from a track-and-trace bolt-on to a strategic data platform \u2013 with API exposure for regulators and coupling to the European Health Data Space.<\/li>\n<li style=\"margin-bottom:12px;\"><strong style=\"color:#c0392b;\">Data model is consolidating.<\/strong> In addition to the current data matrix code, structured supply chain events, aggregation at the carton level, and harmonized interfaces to national hubs are coming.<\/li>\n<li><strong style=\"color:#c0392b;\">Mid-sized businesses beware.<\/strong> Those planning now should build along the upcoming supply chain events \u2013 not along today&#8217;s EMVS fields. Standard suite upgrades alone won&#8217;t be enough.<\/li>\n<\/ul>\n<\/div>\n<p style=\"font-size:0.88em;color:#666;margin:20px 0 32px 0;border-top:1px solid #e5e5e5;border-bottom:1px solid #e5e5e5;padding:10px 0;\"><span style=\"color:#202528;font-weight:700;text-transform:uppercase;font-size:0.72em;letter-spacing:0.14em;margin-right:14px;\">Related<\/span><a href=\"https:\/\/mybusinessfuture.com\/en\/546-medicines-unavailable-how-the-critical-medicines-act-drives-reshoring\/\" style=\"color:#333;text-decoration:underline;\">Critical Medicines Act: Reshoring in the pharmaceutical supply chain<\/a>&nbsp;&nbsp;<span style=\"color:#ccc;\">\/<\/span>&nbsp;&nbsp;<a href=\"https:\/\/mybusinessfuture.com\/en\/german-medtech-smes-in-2026-simultaneous-pressure-from-mdr-nis2-pfas-and-us-tari\/\" style=\"color:#333;text-decoration:underline;\">Medtech SMEs: MDR, NIS2, and PFAS in interplay<\/a><\/p>\n<p style=\"line-height:1.8;margin-bottom:20px;\">The FMD was adopted in 2011, specified in 2016 by Delegated Regulation 2016\/161, and has been operational since 2019. The revision discussion initiated by the EU Commission in 2024 with a consultation aims not to replace the system but to improve data quality and tighten its connection to regimes like the European Health Data Space. For IT decision-makers, this means: the infrastructure is in place, but the data points are becoming denser.<\/p>\n<h2 style=\"padding-top:64px;margin-bottom:20px;\">What the FMD revision specifically changes<\/h2>\n<p style=\"line-height:1.8;margin-bottom:20px;\">The EU Commission proposed the revision of the pharmaceutical legislation in 2023 and launched a public consultation on supply chain and counterfeit protection in 2024. The FMD is one of several building blocks in this package. What is emerging from the consultation documents and the accompanying statements from the EMA can be summarized in three key developments.<\/p>\n<p style=\"line-height:1.8;margin-bottom:20px;\">Firstly, an increase in data quality density. The current FMD requires minimum data to be sent to the hub: product code, serial number, batch, and expiration date. The discussion is now around structured supply chain events \u2013 i.e., notifications when a batch leaves the manufacturer, arrives at a wholesaler, or undergoes repackaging. This is not a new data type, but rather a different level of granularity.<\/p>\n<p style=\"line-height:1.8;margin-bottom:20px;\">Secondly, a closer coupling with the European Health Data Space and supply chain transparency initiatives such as the Critical Medicines Act. The idea is that if a medicine needs to be tracked during a shortage, the path from the EMVS to aggregation dashboards should be shorter than it is today.<\/p>\n<p style=\"line-height:1.8;margin-bottom:20px;\">Thirdly, a harmonization of national hubs. The consultation raises the question of whether data schemas and interfaces should be more centrally prescribed in the future. For manufacturers operating in multiple markets, this would be a simplification \u2013 but only if their own systems are adapted to a uniform schema.<\/p>\n<div style=\"overflow-x:auto;margin:32px 0;\">\n<table style=\"width:100%;border-collapse:collapse;font-size:0.95em;\">\n<thead>\n<tr style=\"background:#202528;color:#fff;\">\n<th style=\"padding:12px 16px;text-align:left;border:1px solid #202528;\">Aspect<\/th>\n<th style=\"padding:12px 16px;text-align:left;border:1px solid #202528;\">FMD today (as of 2019)<\/th>\n<th style=\"padding:12px 16px;text-align:left;border:1px solid #202528;\">FMD revision (discussion status 2026)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:12px 16px;border:1px solid #ddd;\"><strong>Data depth<\/strong><\/td>\n<td style=\"padding:12px 16px;border:1px solid #ddd;\">Product code, serial number, batch, expiration date<\/td>\n<td style=\"padding:12px 16px;border:1px solid #ddd;color:#202528;font-weight:600;\">Plus structured supply chain events (manufacturer exit, wholesaler receipt, repackaging)<\/td>\n<\/tr>\n<tr style=\"background:#fafafa;\">\n<td style=\"padding:12px 16px;border:1px solid #ddd;\"><strong>Aggregation<\/strong><\/td>\n<td style=\"padding:12px 16px;border:1px solid #ddd;\">Individual packaging, national repositories<\/td>\n<td style=\"padding:12px 16px;border:1px solid #ddd;color:#202528;font-weight:600;\">Case level under discussion, harmonized interfaces<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:12px 16px;border:1px solid #ddd;\"><strong>Coupling<\/strong><\/td>\n<td style=\"padding:12px 16px;border:1px solid #ddd;\">EMVS only<\/td>\n<td style=\"padding:12px 16px;border:1px solid #ddd;color:#202528;font-weight:600;\">Connection to European Health Data Space and Critical Medicines Act<\/td>\n<\/tr>\n<tr style=\"background:#fafafa;\">\n<td style=\"padding:12px 16px;border:1px solid #ddd;\"><strong>IT impact<\/strong><\/td>\n<td style=\"padding:12px 16px;border:1px solid #ddd;\">Track-and-trace bolt-on, ERP interface<\/td>\n<td style=\"padding:12px 16px;border:1px solid #ddd;color:#202528;font-weight:600;\">Serialization layer as a strategic data platform with API exposure<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"font-size:0.8em;color:#888;margin-top:8px;\">Source: EU Commission Pharma Package 2023, public consultation 2024, EMVO materials. Classification: Discussion and draft status, not final legal situation.<\/p>\n<\/div>\n<h2 style=\"padding-top:64px;margin-bottom:20px;\">The Regulatory Roadmap<\/h2>\n<p style=\"line-height:1.8;margin-bottom:20px;\">The FMD didn&#8217;t come into being overnight. To understand the revision, it&#8217;s essential to look at the journey since 2011.<\/p>\n<div style=\"margin:32px 0;\">\n<div style=\"display:flex;gap:16px;margin-bottom:16px;border-left:3px solid #c0392b;padding-left:20px;\">\n<div style=\"min-width:90px;font-weight:700;color:#c0392b;\">2011<\/div>\n<div style=\"color:#333;line-height:1.6;\">Directive 2011\/62\/EU (Falsified Medicines Directive) is adopted \u2013 legal framework for safety features on medicinal product packaging.<\/div>\n<\/div>\n<div style=\"display:flex;gap:16px;margin-bottom:16px;border-left:3px solid #c0392b;padding-left:20px;\">\n<div style=\"min-width:90px;font-weight:700;color:#c0392b;\">2016<\/div>\n<div style=\"color:#333;line-height:1.6;\">Delegated Regulation (EU) 2016\/161 specifies the Datamatrix code, Tamper-Evident Feature, and the End-to-End verification system with EU Hub and national repositories.<\/div>\n<\/div>\n<div style=\"display:flex;gap:16px;margin-bottom:16px;border-left:3px solid #c0392b;padding-left:20px;\">\n<div style=\"min-width:90px;font-weight:700;color:#c0392b;\">9 Feb 2019<\/div>\n<div style=\"color:#333;line-height:1.6;\">Operational obligation comes into effect. Manufacturers upload serialization data to the EU Hub, pharmacies verify during dispensing. Germany introduces securPharm as its national hub.<\/div>\n<\/div>\n<div style=\"display:flex;gap:16px;margin-bottom:16px;border-left:3px solid #c0392b;padding-left:20px;\">\n<div style=\"min-width:90px;font-weight:700;color:#c0392b;\">2023<\/div>\n<div style=\"color:#333;line-height:1.6;\">EU Commission presents drafts for the revision of pharmaceutical legislation. FMD becomes part of a larger reform package.<\/div>\n<\/div>\n<div style=\"display:flex;gap:16px;margin-bottom:16px;border-left:3px solid #c0392b;padding-left:20px;\">\n<div style=\"min-width:90px;font-weight:700;color:#c0392b;\">2024<\/div>\n<div style=\"color:#333;line-height:1.6;\">Public consultation on supply chain transparency and counterfeit protection. Parallel: Critical Medicines Act explores connection with shortage management.<\/div>\n<\/div>\n<div style=\"display:flex;gap:16px;margin-bottom:16px;border-left:3px solid #c0392b;padding-left:20px;\">\n<div style=\"min-width:90px;font-weight:700;color:#c0392b;\">2025 \/ 26<\/div>\n<div style=\"color:#333;line-height:1.6;\">Revision phase: trilogue negotiations, shaping delegated acts. Concrete implementation dates for expanded data points are subject to consultations.<\/div>\n<\/div>\n<\/div>\n<h2 style=\"padding-top:64px;margin-bottom:20px;\">What Manufacturers&#8217; IT Must Adjust Now<\/h2>\n<p style=\"line-height:1.8;margin-bottom:20px;\">The operational systems for serialization have been in operation at almost all manufacturers since 2019. The question is not whether a line can code, but how robust the data chain is from the packaging process through the Level 4 repository to the national hub.<\/p>\n<div style=\"display:grid;grid-template-columns:repeat(auto-fit,minmax(280px,1fr));gap:16px;margin:28px 0;\">\n<div style=\"background:#fafafa;border-top:3px solid #c0392b;padding:18px 20px;border-radius:4px;\">\n<p style=\"margin:0 0 10px 0;font-size:0.78em;font-weight:700;text-transform:uppercase;letter-spacing:0.12em;color:#c0392b;\">What Breaks First<\/p>\n<ul style=\"margin:0;padding-left:18px;color:#333;line-height:1.55;font-size:0.95em;\">\n<li style=\"margin-bottom:6px;\">Mask integration in ERP (SAP ATTP, Oracle OPM) for new event types<\/li>\n<li style=\"margin-bottom:6px;\">Aggregation logic when the carton level becomes mandatory<\/li>\n<li style=\"margin-bottom:6px;\">Repackaging workflows for parallel importers<\/li>\n<li>Monitoring dashboards that only look as far as the national hub<\/li>\n<\/ul>\n<\/div>\n<div style=\"background:#fafafa;border-top:3px solid #2d7a3e;padding:18px 20px;border-radius:4px;\">\n<p style=\"margin:0 0 10px 0;font-size:0.78em;font-weight:700;text-transform:uppercase;letter-spacing:0.12em;color:#2d7a3e;\">What Already Works Today<\/p>\n<ul style=\"margin:0;padding-left:18px;color:#333;line-height:1.55;font-size:0.95em;\">\n<li style=\"margin-bottom:6px;\">Event-based architectures (Kafka, Pub\/Sub) instead of batch uploads<\/li>\n<li style=\"margin-bottom:6px;\">Clean separation of master data from transactional data in serialization<\/li>\n<li style=\"margin-bottom:6px;\">Versioned interface contracts with hubs and wholesalers<\/li>\n<li>Mock hub tests as part of the release pipeline, not as an annual exercise<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<p style=\"line-height:1.8;margin-bottom:20px;\">In a standard setup, a Level 4 solution like SAP ATTP or TraceLink takes on the role of the central serialization repository. ATTP is tightly integrated with SAP S\/4HANA, while TraceLink is often chosen for heterogeneous ERP landscapes or strong CMO networking and provides EU hub connectivity as a managed service. Both cover today&#8217;s FMD requirements in a standardized manner.<\/p>\n<p style=\"line-height:1.8;margin-bottom:20px;\">The new effort comes less from new functions than from what&#8217;s beneath the surface: Master Data Governance (are product codes and GTINs consistent?), EDI connections to wholesalers, interfaces for batch release from MES and QMS, aggregation at the pallet and shipping level. If the revision demands additional events, these transitions are the bottlenecks.<\/p>\n<h2 style=\"padding-top:64px;margin-bottom:20px;\">Standard Suite or Custom Development<\/h2>\n<p style=\"line-height:1.8;margin-bottom:20px;\">For mid-sized companies, the architecture question regularly arises: Is the in-house solution from 2019 sufficient for the next stage of expansion, or is it time to switch to a standard suite?<\/p>\n<blockquote style=\"border-left:4px solid #c0392b;background:linear-gradient(135deg,#fff5f5 0%,#ffe8e6 100%);padding:24px 28px;margin:32px 0;font-style:italic;font-size:1.1em;color:#202528;border-radius:4px;\"><p>\nSerialization is no longer just a compliance requirement. Anyone who treats the revision as a simple add-on to the existing track-and-trace solution is building a system that will be replaced again in 2028.\n<\/p><\/blockquote>\n<div style=\"display:flex;gap:16px;margin:32px 0;flex-wrap:wrap;\">\n<div style=\"flex:1;min-width:280px;background:#f0faf0;border-radius:8px;padding:16px 20px;border-top:3px solid #2ecc71;\">\n<p style=\"margin:0 0 12px;font-weight:700;color:#2ecc71;\">Standard Suite (SAP ATTP \/ TraceLink)<\/p>\n<ul style=\"margin:0;padding-left:18px;line-height:1.7;\">\n<li>EU hub connection as a managed service; release changes follow regulatory requirements.<\/li>\n<li>Established EDI connectors to major wholesalers and CMO networks.<\/li>\n<li>Support contracts and audit trail according to GxP logic.<\/li>\n<li>High licensing and integration costs; dependence on the vendor&#8217;s roadmap.<\/li>\n<\/ul>\n<\/div>\n<div style=\"flex:1;min-width:280px;background:#fdf0f0;border-radius:8px;padding:16px 20px;border-top:3px solid #e74c3c;\">\n<p style=\"margin:0 0 12px;font-weight:700;color:#e74c3c;\">Custom Development \/ Minimal Setup<\/p>\n<ul style=\"margin:0;padding-left:18px;line-height:1.7;\">\n<li>Lower ongoing licensing costs; full control over the data model.<\/li>\n<li>Often sufficient as long as only FMD mandatory data points are relevant.<\/li>\n<li>Weakness in scaling \u2013 new events, new market connections, and EHDS interfaces require custom development.<\/li>\n<li>Validation effort and GxP documentation remain with the manufacturer.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<p style=\"line-height:1.8;margin-bottom:20px;\">The decisive factor rarely lies in the company size, but rather in the number of production sites, CMO partners, and target markets. The more fragmented the network, the more expensive custom development becomes, especially when the revision demands additional data points.<\/p>\n<h2 style=\"padding-top:64px;margin-bottom:20px;\">Where Mid-Sized Companies Realistically Struggle<\/h2>\n<p style=\"line-height:1.8;margin-bottom:20px;\">In discussions with IT decision-makers at mid-sized manufacturers, a common pattern emerges. The line connection works, the hub upload runs smoothly, and verification alerts are handled. The pain point lies further back: in the data pipelines that connect serialization information to the rest of the company.<\/p>\n<p style=\"line-height:1.8;margin-bottom:20px;\">Typical gaps include inconsistent master data between ERP, MES, and Level 4 solutions. Batch information that is only partially automated from QMS releases into the serialization chain. EDI routes to wholesalers that still export shipping notices via CSV or PDF. And a repository that serves the EU hub but cannot provide clean evaluations of batch and serial number histories when a regulatory authority requests them.<\/p>\n<p style=\"line-height:1.8;margin-bottom:20px;\">When the FMD revision adds structured supply chain events in the coming years, these are exactly the points that will break. Those who manage without master data governance today will have to rework each new data point individually tomorrow. The proposed EHDS connection does not simplify the picture \u2013 it assumes that a manufacturer internally knows which data they actually have clean.<\/p>\n<h2 style=\"padding-top:64px;margin-bottom:20px;\">Data Points Under Discussion<\/h2>\n<p style=\"line-height:1.8;margin-bottom:20px;\">The consultation responses and position papers from the <a href=\"https:\/\/www.efpia.eu\/\">EFPIA<\/a>, generics associations, and the European Medicines Verification Organisation (EMVO) highlight recurring themes. These are not yet finalized changes, but they indicate the direction of the ongoing discussions.<\/p>\n<p style=\"line-height:1.8;margin-bottom:20px;\">Firstly, structured shipping events along the wholesale route. Currently, manufacturers report when a product is placed on the market, and pharmacies report when it&#8217;s dispensed. The EMVS is &#8220;blind&#8221; to the events in between. The discussion is centered around aggregation reporting at the pallet and carton level to enable faster access to inventory data during recalls and shortages.<\/p>\n<p style=\"line-height:1.8;margin-bottom:20px;\">Secondly, a cleaner integration with supply chain transparency regimes. The Critical Medicines Act aims to keep critical active ingredients and finished products under surveillance across Europe. Those already required to maintain origin data per batch will be able to provide this information from the serialization repository \u2013 assuming master data hygiene is in order.<\/p>\n<p style=\"line-height:1.8;margin-bottom:20px;\">Thirdly, closer integration with the <a href=\"https:\/\/health.ec.europa.eu\/ehealth-digital-health-and-care\/european-health-data-space_en\">European Health Data Space<\/a>. For pharmaceuticals, this doesn&#8217;t mean verification data will be transferred to patient dossiers. The discussion revolves around aggregated consumption and inventory data, which should be made available in a structured manner to authorities and secondary research. The FMD infrastructure is a logical source for this data.<\/p>\n<h2 style=\"padding-top:64px;margin-bottom:20px;\">Shifting Cost Dynamics<\/h2>\n<p style=\"line-height:1.8;margin-bottom:20px;\">The initial FMD investments between 2016 and 2019 were substantial for many manufacturers, ranging from six-figure to low seven-figure sums per site \u2013 including line equipment, Level 3 cameras, Level 4 repository, hub connection, and validation. Ongoing operations are significantly cheaper but still run into the mid-six-figure range per year, depending on the setup and product portfolio.<\/p>\n<div style=\"background:#202528;color:#fff;text-align:center;padding:40px 24px;margin:32px 0;border-radius:8px;\">\n<div style=\"font-size:3.4em;font-weight:800;color:#c0392b;letter-spacing:-0.03em;line-height:1;\">over 20 billion<\/div>\n<div style=\"font-size:1em;color:rgba(255,255,255,0.88);margin-top:12px;max-width:520px;margin-left:auto;margin-right:auto;line-height:1.5;\">serialized packs pass through the European Medicines Verification System annually \u2013 each triggering a transaction that is set to carry additional events in the revision<\/div>\n<div style=\"font-size:0.78em;color:rgba(255,255,255,0.5);margin-top:12px;\">Source: European Medicines Verification Organisation (EMVO), Annual Report 2024<\/div>\n<\/div>\n<p style=\"line-height:1.8;margin-bottom:20px;\">A revision will primarily alter this structure at two points. For standard suites, additional data points typically arrive via release upgrades covered by the maintenance contract \u2013 the actual work lies in customizing and validating the new configuration. For custom developments, the effort falls entirely in-house and scales with the number of connections and markets. Depending on the expansion stage, this can significantly drive up ongoing costs.<\/p>\n<p style=\"line-height:1.8;margin-bottom:20px;\">The strategic question for mid-market IT leaders is less about whether a standard suite makes financial sense, but rather when. Those who start in 2026 and plan for a two-year migration period will hit a new FMD expansion stage with a robust platform. Those who react only when the delegated acts are in place risk running into the classic bottleneck of license negotiations, integrator capacity, and audit appointments.<\/p>\n<h2 style=\"padding-top:64px;margin-bottom:20px;\">What this means for the next 24 months<\/h2>\n<p style=\"line-height:1.8;margin-bottom:20px;\">Panic is not the right mode. The FMD infrastructure is in place, and the standard suites are delivering. The revision will come with lead times that allow for planning. What makes sense now is an honest inventory: Which data points are currently passing through the serialization repository, which ones are only partially processed, and which ones are not at all? Where are the EDI and ERP interfaces fragile?<\/p>\n<div style=\"margin:28px 0;border:1px solid #e5e5e5;border-radius:6px;overflow:hidden;\">\n<div style=\"background:#202528;color:#fff;padding:12px 18px;font-size:0.78em;font-weight:700;text-transform:uppercase;letter-spacing:0.14em;\">The next milestones<\/div>\n<div style=\"padding:8px 0;\">\n<div style=\"display:flex;gap:18px;padding:12px 20px;border-bottom:1px solid #f0f0f0;\">\n<div style=\"min-width:110px;font-weight:700;color:#c0392b;\">H2 2026<\/div>\n<div style=\"color:#333;line-height:1.55;\">Completion of the public consultation, first trilogue negotiations on the pharmaceutical package<\/div>\n<\/div>\n<div style=\"display:flex;gap:18px;padding:12px 20px;border-bottom:1px solid #f0f0f0;\">\n<div style=\"min-width:110px;font-weight:700;color:#c0392b;\">2027<\/div>\n<div style=\"color:#333;line-height:1.55;\">Possible adoption of the revision package, start of detailed delegated acts on serialization and aggregation<\/div>\n<\/div>\n<div style=\"display:flex;gap:18px;padding:12px 20px;border-bottom:1px solid #f0f0f0;\">\n<div style=\"min-width:110px;font-weight:700;color:#c0392b;\">2028<\/div>\n<div style=\"color:#333;line-height:1.55;\">First pilot integrations EMVS &harr; European Health Data Space, mock hub tests of new event types<\/div>\n<\/div>\n<div style=\"display:flex;gap:18px;padding:12px 20px;\">\n<div style=\"min-width:110px;font-weight:700;color:#c0392b;\">from 2029<\/div>\n<div style=\"color:#333;line-height:1.55;\">Gradual go-live of harmonized interfaces, replacement of old bolt-on solutions in manufacturer IT<\/div>\n<\/div>\n<\/div>\n<p style=\"font-size:0.75em;color:#888;margin:8px 20px 16px 20px;\">Timings: Discussion status as of April 2026. Official dates will only be fixed during the trilogue negotiations.<\/p>\n<\/div>\n<p style=\"line-height:1.8;margin-bottom:20px;\">Those who conduct this inventory properly will have a realistic basis to decide in two to three years whether the existing solution can be adapted with manageable adjustments \u2013 or whether the revision is the moment when switching to a standard suite makes more sense than the next custom-built release.<\/p>\n<p style=\"line-height:1.8;margin-bottom:20px;\">As of April 2026, no final dates have been set for extended FMD data points. Those who use the time to consolidate master data, EDI routes, and repository connections will have a solid foundation for any conceivable expansion stage, rather than patchwork solutions.<\/p>\n<h2 style=\"padding-top:64px;margin-bottom:8px;\">Frequently Asked Questions<\/h2>\n<details style=\"border:1px solid #e9ecef;border-radius:6px;background:#f8f9fa;margin-bottom:8px;\">\n<summary style=\"padding:14px 18px;cursor:pointer;font-weight:600;\"><strong>What exactly is the EU Falsified Medicines Directive (FMD)?<\/strong><\/summary>\n<p style=\"padding:14px 20px 18px;color:#495057;line-height:1.7;\">The FMD is the EU directive to combat counterfeit medicines in the legal supply chain. Since 2019, it has obligated manufacturers of prescription human medicines to equip every pack with a unique 2D datamatrix code and a tamper-evident device. Pharmacies and clinics verify the packs via the European verification system before dispensing.<\/p>\n<\/details>\n<details style=\"border:1px solid #e9ecef;border-radius:6px;background:#f8f9fa;margin-bottom:8px;\">\n<summary style=\"padding:14px 18px;cursor:pointer;font-weight:600;\"><strong>What role does the 2D code play in serialization?<\/strong><\/summary>\n<p style=\"padding:14px 20px 18px;color:#495057;line-height:1.7;\">The 2D datamatrix code carries the serialized pack data, typically GTIN, serial number, batch number, and expiry date. It is the central interface between manufacturers, the EU hub, and national repositories. Without a cleanly printed, machine-readable code, a pack cannot be resolved in the verification process and is considered non-dispensable.<\/p>\n<\/details>\n<details style=\"border:1px solid #e9ecef;border-radius:6px;background:#f8f9fa;margin-bottom:8px;\">\n<summary style=\"padding:14px 18px;cursor:pointer;font-weight:600;\"><strong>What is the EU hub and what function does it have in the architecture?<\/strong><\/summary>\n<p style=\"padding:14px 20px 18px;color:#495057;line-height:1.7;\">The EU hub is the central hub operated by the European Medicines Verification Organisation, into which manufacturers upload their pack data. From there, the data is distributed to national repositories, where pharmacies and clinics perform verification. The hub is the technical foundation for any discussion about expanded data points or new verification steps.<\/p>\n<\/details>\n<details style=\"border:1px solid #e9ecef;border-radius:6px;background:#f8f9fa;margin-bottom:8px;\">\n<summary style=\"padding:14px 18px;cursor:pointer;font-weight:600;\"><strong>What does aggregation mean in the pharmaceutical supply chain?<\/strong><\/summary>\n<p style=\"padding:14px 20px 18px;color:#495057;line-height:1.7;\">Aggregation describes the hierarchical linking of individual packs, cartons, bundles, and pallets via the serialization infrastructure. The goal is that a single scan at the pallet level can retrieve all contained packs. In several US and Asian markets, aggregation is already mandatory; in Europe, it remains optional as of April 2026 and is the subject of ongoing discussions.<\/p>\n<\/details>\n<details style=\"border:1px solid #e9ecef;border-radius:6px;background:#f8f9fa;margin-bottom:8px;\">\n<summary style=\"padding:14px 18px;cursor:pointer;font-weight:600;\"><strong>What steps should IT and supply chain managers take in 2026?<\/strong><\/summary>\n<p style=\"padding:14px 20px 18px;color:#495057;line-height:1.7;\">An honest inventory of the serialization landscape is the starting point. Which lines print which data points, which systems write to which repository, where are EDI and ERP interfaces fragile? Based on this, it can be decided whether an existing solution can be adapted or if the upcoming revision is the right moment to switch to a standard suite.<\/p>\n<\/details>\n<p style=\"text-align:right;font-style:italic;color:#888;font-size:0.85em;\">Source title image: Pexels \/ Tiger Lily (px:4483941)<\/p>\n<div style=\"margin:40px 0;padding:0;border-top:2px solid #202528;\">\n<p style=\"margin:0;padding:16px 0 8px 0;font-size:0.78em;font-weight:700;text-transform:uppercase;letter-spacing:0.18em;color:#202528;\">Editor&#8217;s Picks<\/p>\n<ul style=\"list-style:none;margin:0;padding:0;\">\n<li style=\"padding:10px 0;border-bottom:1px solid #eee;\"><a href=\"https:\/\/mybusinessfuture.com\/en\/546-medicines-unavailable-how-the-critical-medicines-act-drives-reshoring\/\" style=\"color:#1a1a1a;text-decoration:none;\">Critical Medicines Act: Reshoring in the pharmaceutical supply chain<\/a><\/li>\n<li style=\"padding:10px 0;border-bottom:1px solid #eee;\"><a href=\"https:\/\/mybusinessfuture.com\/en\/ehds-is-law-what-the-european-health-data-space-means-for-businesses\/\" style=\"color:#1a1a1a;text-decoration:none;\">EHDS is law: What the European Health Data Space brings<\/a><\/li>\n<li style=\"padding:10px 0;\"><a href=\"https:\/\/mybusinessfuture.com\/en\/german-medtech-smes-in-2026-simultaneous-pressure-from-mdr-nis2-pfas-and-us-tari\/\" style=\"color:#1a1a1a;text-decoration:none;\">Medtech SMEs: Mastering compliance risks and growing<\/a><\/li>\n<\/ul>\n<\/div>\n<div style=\"margin:40px 0 24px 0;\">\n<p style=\"margin:0 0 12px 0;font-size:0.78em;font-weight:700;text-transform:uppercase;letter-spacing:0.18em;color:#666;\">More from the MBF Media Network<\/p>\n<div style=\"padding:14px 18px;border-left:3px solid #0bb7fd;background:#fafafa;margin-bottom:6px;\">\n<div style=\"font-size:0.7em;font-weight:700;color:#0bb7fd;text-transform:uppercase;letter-spacing:0.12em;margin-bottom:4px;\">cloudmagazin<\/div>\n<p><a href=\"https:\/\/www.cloudmagazin.com\/en\/2026\/04\/11\/platform-engineering-2026\/\" style=\"font-weight:600;line-height:1.4;color:#1a1a1a;text-decoration:none;\">Platform Engineering 2026: Internal Developer Platforms<\/a>\n<\/div>\n<div style=\"padding:14px 18px;border-left:3px solid #69d8ed;background:#fafafa;margin-bottom:6px;\">\n<div style=\"font-size:0.7em;font-weight:700;color:#69d8ed;text-transform:uppercase;letter-spacing:0.12em;margin-bottom:4px;\">securitytoday<\/div>\n<p><a href=\"https:\/\/www.securitytoday.de\/en\/2026\/04\/13\/nis2-crisis-2026-three-reporting-channels-companies-need-in\/\" style=\"font-weight:600;line-height:1.4;color:#1a1a1a;text-decoration:none;\">NIS2 emergency: Three reporting channels in the first incident hour<\/a>\n<\/div>\n<div style=\"padding:14px 18px;border-left:3px solid #d65663;background:#fafafa;\">\n<div style=\"font-size:0.7em;font-weight:700;color:#d65663;text-transform:uppercase;letter-spacing:0.12em;margin-bottom:4px;\">digital-chiefs<\/div>\n<p><a href=\"https:\/\/www.digital-chiefs.de\/en\/cloud-repatriation-2026-statistical-illusion\/\" style=\"font-weight:600;line-height:1.4;color:#1a1a1a;text-decoration:none;\">Cloud Repatriation 2026: Hybrid architecture in the CIO&#8217;s view<\/a>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The FMD revision arrives without compliance panic. What changes regarding data points, how SAP ATTP and TraceLink are positioned, and where mid-sized companies face challenges.<\/p>\n","protected":false},"author":160,"featured_media":97271,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_yoast_wpseo_focuskw":"EU FMD compliance","_yoast_wpseo_title":"Pharma Serialization 2.0: What the EU-FMD Revision Means for IT and Supply Chain","_yoast_wpseo_metadesc":"FMD Revision: Key data points, SAP ATTP & TraceLink setup, and gaps mid-sized companies realistically face.","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","_yoast_wpseo_meta-robots-adv":"","_yoast_wpseo_canonical":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":0,"_yoast_wpseo_twitter-title":"","_yoast_wpseo_twitter-description":"","_yoast_wpseo_twitter-image":"","_yoast_wpseo_twitter-image-id":0,"featured_post_sortierung":0,"featured_post":0,"pre_headline":"","bildquelle":"","teasertext":"","language":"de","_evm_translation_lang":"","_wp_old_slug":[],"footnotes":""},"categories":[1146],"tags":[],"class_list":["post-97464","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-sciences-health-care","entry"],"evm_reading_time_minutes":14,"wpml_language":"en","wpml_translation_of":97230,"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharma Serialization 2.0: What the EU-FMD Revision Means for IT and Supply Chain<\/title>\n<meta name=\"description\" content=\"FMD Revision: Key data points, SAP ATTP &amp; TraceLink setup, and gaps mid-sized companies realistically face.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma Serialization 2.0: What the EU-FMD Revision Means for IT and Supply Chain\" \/>\n<meta property=\"og:description\" content=\"FMD Revision: Key data points, SAP ATTP &amp; TraceLink setup, and gaps mid-sized companies realistically face.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/\" \/>\n<meta property=\"og:site_name\" content=\"MyBusinessFuture\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/MyBusinessFuture\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-21T12:39:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-10T14:01:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mybusinessfuture.com\/wp-content\/uploads\/2026\/04\/mbf-pharma-warehouse-scanner.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1880\" \/>\n\t<meta property=\"og:image:height\" content=\"1253\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benedikt Langer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@mbusinessfuture\" \/>\n<meta name=\"twitter:site\" content=\"@mbusinessfuture\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benedikt Langer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/\"},\"author\":{\"name\":\"Benedikt Langer\",\"@id\":\"https:\/\/mybusinessfuture.com\/#\/schema\/person\/2c6c900f809c3c375dc455db50d1e7b1\"},\"headline\":\"EU-FMD Revision: IT &amp; Supply Chain Impact\",\"datePublished\":\"2026-04-21T12:39:16+00:00\",\"dateModified\":\"2026-06-10T14:01:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/\"},\"wordCount\":2406,\"publisher\":{\"@id\":\"https:\/\/mybusinessfuture.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mybusinessfuture.com\/wp-content\/uploads\/2026\/04\/mbf-pharma-warehouse-scanner.jpg\",\"articleSection\":[\"Life Sciences &amp; Health Care\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/\",\"url\":\"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/\",\"name\":\"Pharma Serialization 2.0: What the EU-FMD Revision Means for IT and Supply Chain\",\"isPartOf\":{\"@id\":\"https:\/\/mybusinessfuture.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mybusinessfuture.com\/wp-content\/uploads\/2026\/04\/mbf-pharma-warehouse-scanner.jpg\",\"datePublished\":\"2026-04-21T12:39:16+00:00\",\"dateModified\":\"2026-06-10T14:01:35+00:00\",\"description\":\"FMD Revision: Key data points, SAP ATTP & TraceLink setup, and gaps mid-sized companies realistically face.\",\"breadcrumb\":{\"@id\":\"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/#primaryimage\",\"url\":\"https:\/\/mybusinessfuture.com\/wp-content\/uploads\/2026\/04\/mbf-pharma-warehouse-scanner.jpg\",\"contentUrl\":\"https:\/\/mybusinessfuture.com\/wp-content\/uploads\/2026\/04\/mbf-pharma-warehouse-scanner.jpg\",\"width\":1880,\"height\":1253,\"caption\":\"Quelle: Pexels \/ Tiger Lily (px:4483941)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/mybusinessfuture.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EU-FMD Revision: IT &amp; Supply Chain Impact\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mybusinessfuture.com\/#website\",\"url\":\"https:\/\/mybusinessfuture.com\/\",\"name\":\"MyBusinessFuture\",\"description\":\"B2B-Magazin f\u00fcr Digitalisierung, KI und Business-Innovation \u2014 Fachartikel f\u00fcr IT-Entscheider im DACH-Raum\",\"publisher\":{\"@id\":\"https:\/\/mybusinessfuture.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mybusinessfuture.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mybusinessfuture.com\/#organization\",\"name\":\"MyBusinessFuture\",\"url\":\"https:\/\/mybusinessfuture.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mybusinessfuture.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mybusinessfuture.com\/wp-content\/uploads\/2020\/10\/MBF-logo-schwarz.png\",\"contentUrl\":\"https:\/\/mybusinessfuture.com\/wp-content\/uploads\/2020\/10\/MBF-logo-schwarz.png\",\"width\":398,\"height\":241,\"caption\":\"MyBusinessFuture\"},\"image\":{\"@id\":\"https:\/\/mybusinessfuture.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/MyBusinessFuture\",\"https:\/\/x.com\/mbusinessfuture\",\"https:\/\/www.linkedin.com\/showcase\/mybusinessfuture\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mybusinessfuture.com\/#\/schema\/person\/2c6c900f809c3c375dc455db50d1e7b1\",\"name\":\"Benedikt Langer\",\"description\":\"Benedikt Langer befasst sich als Chefredakteur bei MyBusinessFuture mit Digitalisierung, Cloud-Strategien und KI-Anwendungen f\u00fcr Unternehmen. Mit besonderem Fokus auf K\u00fcnstliche Intelligenz, digitale Infrastruktur und strategische Cloud-Architekturen beleuchtet er technologische Entwicklungen und deren Auswirkungen auf Business-Entscheidungen.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/benedikt-langer\/\",\"https:\/\/www.linkedin.com\/in\/benedikt-langer-574b8a20b\/\"],\"url\":\"https:\/\/mybusinessfuture.com\/en\/experte\/benedikt-langer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharma Serialization 2.0: What the EU-FMD Revision Means for IT and Supply Chain","description":"FMD Revision: Key data points, SAP ATTP & TraceLink setup, and gaps mid-sized companies realistically face.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/","og_locale":"en_US","og_type":"article","og_title":"Pharma Serialization 2.0: What the EU-FMD Revision Means for IT and Supply Chain","og_description":"FMD Revision: Key data points, SAP ATTP & TraceLink setup, and gaps mid-sized companies realistically face.","og_url":"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/","og_site_name":"MyBusinessFuture","article_publisher":"https:\/\/www.facebook.com\/MyBusinessFuture","article_published_time":"2026-04-21T12:39:16+00:00","article_modified_time":"2026-06-10T14:01:35+00:00","og_image":[{"width":1880,"height":1253,"url":"https:\/\/mybusinessfuture.com\/wp-content\/uploads\/2026\/04\/mbf-pharma-warehouse-scanner.jpg","type":"image\/jpeg"}],"author":"Benedikt Langer","twitter_card":"summary_large_image","twitter_creator":"@mbusinessfuture","twitter_site":"@mbusinessfuture","twitter_misc":{"Written by":"Benedikt Langer","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/#article","isPartOf":{"@id":"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/"},"author":{"name":"Benedikt Langer","@id":"https:\/\/mybusinessfuture.com\/#\/schema\/person\/2c6c900f809c3c375dc455db50d1e7b1"},"headline":"EU-FMD Revision: IT &amp; Supply Chain Impact","datePublished":"2026-04-21T12:39:16+00:00","dateModified":"2026-06-10T14:01:35+00:00","mainEntityOfPage":{"@id":"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/"},"wordCount":2406,"publisher":{"@id":"https:\/\/mybusinessfuture.com\/#organization"},"image":{"@id":"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/#primaryimage"},"thumbnailUrl":"https:\/\/mybusinessfuture.com\/wp-content\/uploads\/2026\/04\/mbf-pharma-warehouse-scanner.jpg","articleSection":["Life Sciences &amp; Health Care"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/","url":"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/","name":"Pharma Serialization 2.0: What the EU-FMD Revision Means for IT and Supply Chain","isPartOf":{"@id":"https:\/\/mybusinessfuture.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/#primaryimage"},"image":{"@id":"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/#primaryimage"},"thumbnailUrl":"https:\/\/mybusinessfuture.com\/wp-content\/uploads\/2026\/04\/mbf-pharma-warehouse-scanner.jpg","datePublished":"2026-04-21T12:39:16+00:00","dateModified":"2026-06-10T14:01:35+00:00","description":"FMD Revision: Key data points, SAP ATTP & TraceLink setup, and gaps mid-sized companies realistically face.","breadcrumb":{"@id":"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/#primaryimage","url":"https:\/\/mybusinessfuture.com\/wp-content\/uploads\/2026\/04\/mbf-pharma-warehouse-scanner.jpg","contentUrl":"https:\/\/mybusinessfuture.com\/wp-content\/uploads\/2026\/04\/mbf-pharma-warehouse-scanner.jpg","width":1880,"height":1253,"caption":"Quelle: Pexels \/ Tiger Lily (px:4483941)"},{"@type":"BreadcrumbList","@id":"https:\/\/mybusinessfuture.com\/en\/pharma-serialization-2-0-what-the-eu-fmd-revision-means-for\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/mybusinessfuture.com\/"},{"@type":"ListItem","position":2,"name":"EU-FMD Revision: IT &amp; Supply Chain Impact"}]},{"@type":"WebSite","@id":"https:\/\/mybusinessfuture.com\/#website","url":"https:\/\/mybusinessfuture.com\/","name":"MyBusinessFuture","description":"B2B-Magazin f\u00fcr Digitalisierung, KI und Business-Innovation \u2014 Fachartikel f\u00fcr IT-Entscheider im DACH-Raum","publisher":{"@id":"https:\/\/mybusinessfuture.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mybusinessfuture.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mybusinessfuture.com\/#organization","name":"MyBusinessFuture","url":"https:\/\/mybusinessfuture.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mybusinessfuture.com\/#\/schema\/logo\/image\/","url":"https:\/\/mybusinessfuture.com\/wp-content\/uploads\/2020\/10\/MBF-logo-schwarz.png","contentUrl":"https:\/\/mybusinessfuture.com\/wp-content\/uploads\/2020\/10\/MBF-logo-schwarz.png","width":398,"height":241,"caption":"MyBusinessFuture"},"image":{"@id":"https:\/\/mybusinessfuture.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/MyBusinessFuture","https:\/\/x.com\/mbusinessfuture","https:\/\/www.linkedin.com\/showcase\/mybusinessfuture\/"]},{"@type":"Person","@id":"https:\/\/mybusinessfuture.com\/#\/schema\/person\/2c6c900f809c3c375dc455db50d1e7b1","name":"Benedikt Langer","description":"Benedikt Langer befasst sich als Chefredakteur bei MyBusinessFuture mit Digitalisierung, Cloud-Strategien und KI-Anwendungen f\u00fcr Unternehmen. Mit besonderem Fokus auf K\u00fcnstliche Intelligenz, digitale Infrastruktur und strategische Cloud-Architekturen beleuchtet er technologische Entwicklungen und deren Auswirkungen auf Business-Entscheidungen.","sameAs":["https:\/\/www.linkedin.com\/in\/benedikt-langer\/","https:\/\/www.linkedin.com\/in\/benedikt-langer-574b8a20b\/"],"url":"https:\/\/mybusinessfuture.com\/en\/experte\/benedikt-langer\/"}]}},"_links":{"self":[{"href":"https:\/\/mybusinessfuture.com\/en\/wp-json\/wp\/v2\/posts\/97464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mybusinessfuture.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mybusinessfuture.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mybusinessfuture.com\/en\/wp-json\/wp\/v2\/users\/160"}],"replies":[{"embeddable":true,"href":"https:\/\/mybusinessfuture.com\/en\/wp-json\/wp\/v2\/comments?post=97464"}],"version-history":[{"count":7,"href":"https:\/\/mybusinessfuture.com\/en\/wp-json\/wp\/v2\/posts\/97464\/revisions"}],"predecessor-version":[{"id":109300,"href":"https:\/\/mybusinessfuture.com\/en\/wp-json\/wp\/v2\/posts\/97464\/revisions\/109300"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mybusinessfuture.com\/en\/wp-json\/wp\/v2\/media\/97271"}],"wp:attachment":[{"href":"https:\/\/mybusinessfuture.com\/en\/wp-json\/wp\/v2\/media?parent=97464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mybusinessfuture.com\/en\/wp-json\/wp\/v2\/categories?post=97464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mybusinessfuture.com\/en\/wp-json\/wp\/v2\/tags?post=97464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}